Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03313011 · ClinicalTrials.gov registry record
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
A clinical trial of Primary Progressive Aphasia and Apraxia of Speech, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 47
- Enrollment target
- 1
- Study location
NCT03313011: Recruiting study of Primary Progressive Aphasia and Apraxia of Speech, sponsored by Mayo Clinic.
NCT03313011 is a study of Primary Progressive Aphasia and Apraxia of Speech that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 47 participants, below the 90-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03313011, a study of Primary Progressive Aphasia and Apraxia of Speech, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.
Primary Outcome
Distinguish types of PAOS using the Apraxia of Speech Rating Scale (ASRS)
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Testing protocol for the study
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2027-07 |
What NCT03313011 shows while recruiting
NCT03313011 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 90-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (48% lower).
The record links to 4 conditions, with Primary Progressive Aphasia appearing as the primary indexed condition, and to 1 intervention - of which Testing protocol for the study is the first listed.
NCT03313011 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03313011 about?
NCT03313011 is a clinical study titled "The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech". The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.
What is the current status of trial NCT03313011?
This trial is currently recruiting. The enrollment target is 47 participants. The study started on 2017-08-01. Estimated completion is 2027-07.
What conditions does trial NCT03313011 study?
This clinical trial studies the following conditions: Primary Progressive Aphasia, Apraxia of Speech, Non-fluent Aphasia, Primary Progressive Non-fluent Aphasia.
What interventions are being tested in trial NCT03313011?
The interventions under investigation include: Testing protocol for the study (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03313011?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03313011 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Progressive Aphasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03313011's enrollment target sits among peer trials
47 9th of 15 higher than 7 of 15 other Primary Progressive Aphasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Progressive Aphasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
RECRUITING · Phase 4
-
Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
RECRUITING · Phase 2
-
Language in Primary Progressive Aphasia
RECRUITING
-
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
RECRUITING · Early Phase 1
-
Enhancing Language Function in Aphasia
RECRUITING · NA
-
Enhancing Language Function in Primary Progressive Aphasia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
- NCT04609046 · 47 participants · Phase 1
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI